Neuroprotective effects of statins and cyclodextrin: A Review and the
way forward.
- Qutub Jamali
![](https://d197for5662m48.cloudfront.net/assets/icons/omniauth/orcid-ca37582cd91a671ed5cec57770e0e96c01b4b79b8b5b75d8598fc1ddac18c974.svg)
Abstract
Dementia is a progressive and irreversible deterioration of cognition
which has a significant impact on the person's activities of daily
living and quality of life. Currently, there is no curative treatment of
dementia and the treatment options currently used in clinical practice
has limited therapeutic reach. Although there are ongoing clinical
trials, this review article begins with the question of why statins are
no longer clinically indicated in mild cognitive impairment or mild to
moderate dementia? This review will explore the evidence in support and
against the neuroprotective effects of statins in cognitive impairment.
Whilst exploring the evidence around statins, there emerged a
possibility of another molecule called cyclodextrin which could
potentially not only be a more effective neuroprotective alternative to
statins, but possibly an agent which could potentially improve the early
or mild cognitive deficits. This literature review will hopefully
support in formulating a potential research question for future clinical
trials in the treatment of dementia.Submitted to European Journal of Neuroscience Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
07 Jul 2024Review(s) Completed, Editorial Evaluation Pending